[HTML][HTML] Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk‐guided management
Philadelphia‐negative myeloproliferative neoplasms are considered to be acquired
thrombophilic states. Thromboses, both arterial and venous (not rarely in unusual sites), are …
thrombophilic states. Thromboses, both arterial and venous (not rarely in unusual sites), are …
Splanchnic vein thrombosis in myeloproliferative neoplasms
M Sekhar, K McVinnie… - British journal of …, 2013 - Wiley Online Library
Splanchnic vein thrombosis (SVT) is one of the most important complications of
myeloproliferative neoplasms (MPN). Although MPN are common causes of SVT, the …
myeloproliferative neoplasms (MPN). Although MPN are common causes of SVT, the …
Moving toward disease modification in polycythemia vera
JP Bewersdorf, J How, L Masarova, P Bose… - Blood, 2023 - ashpublications.org
Polycythemia vera (PV) belongs to the BCR-ABL1–negative myeloproliferative neoplasms
and is characterized by activating mutations in JAK2 and clinically presents with …
and is characterized by activating mutations in JAK2 and clinically presents with …
Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis
G Barosi, V Rosti, E Bonetti, R Campanelli, A Carolei… - PloS one, 2012 - journals.plos.org
Purpose In the WHO diagnostic classification, prefibrotic myelofibrosis (pre-MF) is included
in the category of primary myelofibrosis (PMF). However, strong evidence for this position is …
in the category of primary myelofibrosis (PMF). However, strong evidence for this position is …
Age-related differences in disease characteristics and clinical outcomes in polycythemia vera
The natural history and prognosis for young patients with polycythemia vera (PV) in the post-
JAK2 V617F era are not well defined. Therefore, we retrospectively analyzed disease …
JAK2 V617F era are not well defined. Therefore, we retrospectively analyzed disease …
Environmental factors, lifestyle risk factors, and host characteristics associated with philadelphia negative myeloproliferative neoplasm: A systematic review
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders
characterized by the overproduction of mature myeloid cells and are often associated with …
characterized by the overproduction of mature myeloid cells and are often associated with …
Is there a gender effect in polycythemia vera?
F Palandri, B Mora, N Gangat, L Catani - Annals of Hematology, 2021 - Springer
In recent times, there has been a growing interest in understanding the impact of gender on
disease biology and clinical outcomes in Philadelphia-negative chronic myeloproliferative …
disease biology and clinical outcomes in Philadelphia-negative chronic myeloproliferative …
Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth
J Gotlib - Blood, The Journal of the American Society of …, 2022 - ashpublications.org
Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative
neoplasm driven by the JAK2 V617F (or rarely exon 12) mutation. Its natural history can …
neoplasm driven by the JAK2 V617F (or rarely exon 12) mutation. Its natural history can …
New therapeutic approaches in polycythemia vera
L Falchi, KJ Newberry, S Verstovsek - Clinical Lymphoma Myeloma and …, 2015 - Elsevier
Polycythemia vera (PV) is 1 of the 3 Philadelphia-negative myeloproliferative neoplasms.
Clinically, PV is an indolent disease, but its course can be complicated by arterial and …
Clinically, PV is an indolent disease, but its course can be complicated by arterial and …
MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients
H Zhan, C Cardozo, W Yu, A Wang… - Blood Cells, Molecules …, 2013 - Elsevier
Polycythemia vera (PV) and essential thrombocythemia (ET) are the two most common
myeloproliferative neoplasms. The same JAK2V617F mutation can be found in both …
myeloproliferative neoplasms. The same JAK2V617F mutation can be found in both …